ejpmr, 2024, 11(8), 189-196

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

A REVIEW ON FACTORS ASSOCIATED WITH THE DEVELOPMENT OF ALZHEIMER'S IN AUTISTIC PATIENTS

Ankita Anoop[1]*, P. Jayashri Vidya[2], Srimathi M.[3] and Margret Saral M.[4]

[1]Pharm.D, SRM College of Pharmacy, SRM University, Kattankulathur, Chengalpattu District
ankianoop246@gmail.com

[2]Pharm.D, SRM College of Pharmacy, SRM University, Kattankulathur, Chengalpattu District
jayavidya2001@gmail.com

[3]Pharm.D, SRM College of Pharmacy, SRM University, Kattankulathur, Chengalpattu District
msrimathi2002@gmail.com

[4]Pharm.D, SRM College of Pharmacy, SRM University, Kattankulathur, Chengalpattu District
margretsaral280303@gmail.com

***Corresponding Author: Ankita Anoop**

Pharm D., SRM College of Pharmacy, SRM University, Kattankulathur, Chengalpattu District.

Email id: ankianoop246@gmail.com,

Article Received on 15/06/2024 **Article Revised on 05/07/2024** **Article Accepted on 26/07/2024**

ABSTRACT

Alzheimer's disease (AD) and Autism Spectrum Disorder (ASD) are two separate neurological disorders, each with their own pathophysiological characteristics. Newer evidence, however, points to a possible higher risk of AD development in those with ASD. The purpose of this review is to investigate the genetic, neuropathological, inflammatory, metabolic, cognitive, environmental, and psychosocial aspects linked to the onset of Alzheimer's disease in individuals with autism. We uncover common inflammatory pathways, shared neuropathological characteristics, and overlapping genetic markers that may contribute to the elevated risk by a thorough study of the literature that has already been published. Furthermore, we investigate how these two disorders interact with regard to metabolic dysfunction, behavioral and cognitive profiles, environmental exposures, and psychosocial stresses. The review also emphasizes the difficulties in diagnosing this particular patient population and the necessity of coordinated therapeutic approaches. Comprehending these variables is imperative in order to formulate focused interventions and enhance the standard of living for autistic individuals who are susceptible to Alzheimer's disease.

KEYWORDS: Alzheimer's disease (AD), Autism Spectrum Disorder (ASD), Genetic factors, Neuropathology, Inflammation, Metabolic dysfunction, Cognitive decline, Environmental risk factors.

INTRODUTION

The increasing occurrence of neurodevelopmental and neurodegenerative illnesses highlights the need to comprehend their underlying mechanisms and possible intersections. Despite having different traits and different times of onset, Alzheimer's disease (AD) and autism spectrum disorder (ASD) are two examples of such illnesses that share certain comparable pathogenic pathways. In order to shed light on the confluence of these two disorders, this review attempts to investigate the factors linked to the development of Alzheimer's in people with autism.[1,2]

Background on Alzheimer's Disease (AD)

Alzheimer's disease is a neurological illness that worsens with time and is marked by functional impairment, memory loss, and cognitive decline. The buildup of amyloid-beta plaques and neurofibrillary tangles made of tau protein that has been hyperphosphorylated in the brain are two of Alzheimer's disease's signature symptoms. Brain shrinkage is the end result of these degenerative alterations, which also cause synaptic dysfunction and neuronal death. AD is the most prevalent cause of dementia, particularly impacting those over 65. Age, genetic susceptibility (such as APOE gene mutations), cardiovascular health, and lifestyle choices are risk factors for AD. The disease progresses slowly but irreversibly most of the time, which significantly reduces quality of life and everyday functioning.

Background on Autism Spectrum Disorder (ASD)

A complex neurodevelopmental disorder known as autism spectrum disorder is defined by limited, repetitive patterns of behavior, interests, or hobbies, as well as ongoing difficulties in social communication and interaction. ASD can manifest itself in a wide range of ways; some people with the disorder have little symptoms, while others have serious difficulties. Although the precise cause of ASD is still unknown, a combination of genetic and environmental factors is

thought to be the culprit. Since early diagnosis and intervention can greatly improve results, they are essential for controlling ASD. Among the common comorbidities are gastrointestinal problems, epilepsy, and intellectual difficulties.[3,4]

Prevalence of AD in the General Population

With Alzheimer's disease responsible for 60–80% of cases, it is the most frequent cause of dementia. As people age, the prevalence of AD rises dramatically:

- **Overall Prevalence:** 10% of those 65 years of age and above have AD.
- **Age-Specific Prevalence:** After the age of 65, the prevalence doubles roughly every five years, reaching approximately 33% in individuals 85 years of age and above.
- **Gender Differences:** Because women live longer than males, they are more prone to develop AD.
  With an estimated 50 million people suffering from dementia globally, the number is expected to triple by 2050 as a result of aging populations, contributing to a significant and growing global burden of AD.

Prevalence of ASD in the General Population

A common neurodevelopmental disorder with wide variation in presentation is autism spectrum disorder (ASD):

- **Overall Prevalence:** Current projections indicate that 1 in 54 American children receives a diagnosis of ASD.
- **Gender Differences:** Boys are around four times more likely than females to have ASD.
- **Global Prevalence:** Although prevalence numbers can differ between nations and areas, there is a general trend indicating a rise in diagnoses, most likely as a result of increased awareness and better diagnostic procedures.

Typically diagnosed in early childhood, ASD is becoming more widely recognized across the lifetime, which emphasizes the need for ongoing research and aging-in-place support for affected persons.[5,6,7]

FACTORS ASSOCIATED WITH THE DEVELOPMENT OF ALZHEIMERS IN AUTISTIC PATIENTS

Multiple interconnected factors, representing the intricate interplay between neurobiology, genetics, and environmental effects, influence the development of Alzheimer's disease in autistic patients. The common genetic vulnerabilities are a major contributing element. Research has shown shared genetic markers and pathways—such as those pertaining to synaptic function and neuroinflammation—that are connected to both autism spectrum disorder (ASD) and Alzheimer's disease. Furthermore, the pathophysiology of Alzheimer's disease has been connected to mitochondrial dysfunction, a frequent characteristic of ASD, indicating that mitochondrial health may be an important component.

The significance of immunological dysregulation and neuroinflammation is another important factor. Alzheimer's disease-related neurodegenerative processes can be exacerbated in the brain by chronic neuroinflammation, which is frequently seen in people with ASD. The neuronal damage typical of Alzheimer's disease may be accelerated in autistic people due to the constant activation of microglia and increased levels of pro-inflammatory cytokines. Moreover, blood-brain barrier integrity may be compromised in ASD patients, making them more vulnerable to neurodegenerative illnesses.

Significant contributions are also made by lifestyle decisions and environmental circumstances. Owing to dietary inconsistencies or environmental exposures, oxidative stress levels may be higher in autistic people, which might worsen neurodegenerative processes. Alzheimer's disease risk can also be raised by lifestyle characteristics that are more common in the autistic community, such as poor food, social isolation, and inactivity on physical grounds.

Finally, the risk can be increased by co-occurring illnesses and comorbidities in autistic individuals, including metabolic syndromes, sleep disorders, and epilepsy. These disorders may have a direct or indirect impact on the pathways that lead to Alzheimer's pathology in addition to adding to the overall strain on brain systems. In order to address the increased risk of Alzheimer's disease in individuals with autism, it is essential to comprehend these complex relationships in order to design tailored therapies and preventive measures.[8,9,10]

Genetic Factors

Understanding the relationship between autism spectrum disorder (ASD) and Alzheimer's disease (AD) is mostly dependent on genetic variables. The genetic landscapes of both illnesses are complicated, and certain genetic vulnerabilities have been shown to overlap. For example, ASD has also been investigated in relation to mutations in genes that are significantly associated with familial types of AD, such as APP (amyloid precursor protein), PSEN1 (presenilin 1), and PSEN2 (presenilin 2). The processing and accumulation of amyloid-beta, a major pathogenic feature of AD, is mediated by these genes, and the deregulation of these genes may be a factor in the neurodevelopmental abnormalities seen in ASD. Furthermore, similar genetic risk variants have been found for both illnesses, indicating shared underlying mechanisms. These risk variations alter immunological response, synapse function, and neural connection.[11,12]

Neuropathological Overlaps

There are numerous and intricate neurobiological connections between autism spectrum disorder (ASD)

and Alzheimer's disease (AD). ASD patients frequently show changes in synaptic function, neural connection, and neuroinflammatory responses, all of which may put them at higher risk of developing AD in the future. This sensitivity may be attributed to particular genetic variables, such as abnormalities in genes involved in neurodevelopmental processes and synaptic pruning. The risk of AD in autistic people may also be increased by common pathophysiological mechanisms including as mitochondrial dysfunction, oxidative stress, and compromised protein clearance pathways (such autophagy and proteasomal degradation). To mitigate the onset and progression of AD in this susceptible group, specific medicines and interventions must be developed with a thorough understanding of these interconnected neuronal pathways.[13,14]

Role of Inflammation

Alzheimer's disease (AD) is largely caused by inflammation, which affects autistic patients and adds a complicated layer to the illness's progression. There is evidence of chronic neuroinflammation in autistic people, which is typified by activated microglia and raised cytokine levels. This may put autistic people at risk for AD in the future. The deregulation of immunological responses and oxidative stress, which are prevalent in both AD and autism spectrum disorder (ASD), may be connected to this elevated inflammatory state. In addition to causing synaptic dysfunction and neuronal damage, neuroinflammation speeds up the development of tau tangles and amyloid-beta plaques, two of the pathological hallmarks of Alzheimer's disease. The correlation between inflammation and neurodegeneration highlights the significance of focusing on inflammatory pathways as a possible therapeutic approach, customized to the distinct neurobiological characteristics of individuals with autism who are susceptible to Alzheimer's disease. Therefore, comprehending and reducing inflammation in ASD may be promising in postponing or averting the start of Alzheimer's disease in this susceptible group.[15,16]

Immune System Dysregulation

In autistic individuals, immune system dysregulation is a major factor in the onset of Alzheimer's disease (AD), emphasizing the intricate relationships between immunological responses and neuroinflammation. Increased inflammation and immunological activation are common immune profile alterations seen in people with autism spectrum disorder (ASD). This ongoing inflammatory condition could make individuals more vulnerable to the early and accelerated neurodegenerative processes associated with AD. The pathological hallmarks of Alzheimer's disease (AD) include reduced synaptic function and neuronal damage, which can be caused by dysregulated immunological responses, which include increased cytokine production and microglial activation. Furthermore, immune-related environmental variables and genetic predispositions may aggravate these processes in autistic people. Knowing these immune-mediated pathways highlights the possibility for targeted immunomodulatory treatments intended to reduce the incidence of Alzheimer's in this susceptible population, as well as the similarities in processes between ASD and AD.[17,18]

Metabolic and Mitochondrial Dysfunction

There is growing recognition that autism spectrum disorder (ASD) and Alzheimer's disease (AD) are linked by metabolic and mitochondrial abnormalities. Aberrations in mitochondrial activity and metabolic pathways can worsen neurodegenerative processes in individuals with autism who are prone to Alzheimer's disease. Metabolic dysregulation can cause oxidative stress and inflammation, which in turn can contribute to the neuronal damage and cognitive decline observed in Alzheimer's disease (AD). It is commonly characterized by impaired glucose metabolism and altered lipid metabolism. Since mitochondria are vital for energy production, calcium homeostasis, and the control of apoptosis, malfunction in them exacerbates these processes. Mitochondrial dysfunction is already common in ASD, which may make the condition more prone to AD pathology. Reduced ATP production by dysfunctional mitochondria results in a lower supply of energy for neurons and a higher generation of reactive oxygen species (ROS), which exacerbates oxidative damage and neuronal death. Furthermore, mitochondrial failure reduces synaptic plasticity and cellular repair systems, which further compromises cognitive function. It is possible to prevent or delay the onset of AD by treating these metabolic and mitochondrial problems in autistic individuals, highlighting the need for tailored medicines that address the linked pathophysiological pathways of both disorders.[19,20]

Cognitive and Behavioral Factors

Understanding how Alzheimer's disease (AD) develops in autistic persons is mostly dependent on behavioral and cognitive aspects. Different cognitive profiles and behavioral patterns associated with autism spectrum disorder (ASD) can affect how AD manifests and develops. People with autism spectrum disorders (ASD) may have distinct cognitive styles, such as prowess in visual-spatial tasks mixed with difficulties in social cognition and executive function. These cognitive characteristics may influence the development and course of dementia symptoms by interacting with the pathology of Alzheimer's disease. Early indications of AD may sometimes coexist with behavioral symptoms of ASD, including as sensory sensitivity and repetitive activities, making diagnosis and treatment more challenging. Additionally, because people with ASD may exhibit unusual symptom presentations or accelerate cognitive deterioration, doctors must modify diagnostic criteria and evaluations for this population.[21,22]

Environmental and Lifestyle Factors

The chance of Alzheimer's disease (AD) in autistic people is greatly influenced by environmental and

lifestyle factors. Prenatal circumstances and early childhood environments, among other early life experiences and exposures, may have an impact on neurodevelopmental trajectories and predispose individuals to autism spectrum disorder (ASD) and AD in later life. Given the same neurobiological vulnerabilities between ASD and AD, dietary patterns and nutritional status—including shortages in vital nutrients like antioxidants and omega-3 fatty acids—have been linked to neuroprotection and cognitive health. Important roles are also played by social interaction and solitude; people with ASD frequently face particular social difficulties that over time may have an impact on brain health and cognitive performance. Furthermore, lifestyle elements that are linked to the pathophysiology of both ASD and AD, such as levels of physical activity and stress-reduction techniques, may modify neuroinflammation and oxidative stress. Comprehending and tackling these environmental and lifestyle factors is crucial in devising focused therapies meant to mitigate the likelihood or postpone the start of AD in individuals with autism.[23,24]

Psychosocial and Developmental Factors

Developmental and psychosocial factors are important in determining how Alzheimer's disease (AD) develops in individuals with autism. Over time, the difficulties that autistic people frequently have in social contact, communication, and adaptive behavior may have an adverse effect on their cognitive and emotional development. Due to their difficulty establishing and sustaining relationships, autistic people frequently experience social isolation, which may raise their risk of cognitive decline and the onset of Alzheimer's disease. Moreover, autism's sensory sensitivity and repetitive activities may impact brain resilience and plasticity, which may have an impact on the development and course of neurodegenerative diseases like AD. Cognitive outcomes are shaped by developmental factors, which may also influence the risk of Alzheimer's disease in this population. These factors include early childhood experiences, educational treatments, and continuous support networks.[25,26]

Comorbidities and Health Conditions

In autistic people, comorbidities and medical problems are important factors in the development of Alzheimer's disease (AD). Many comorbidities that affect autistic people can increase their chance of developing AD in later life. For example, a significant number of people diagnosed with autism spectrum disorder (ASD) also have higher rates of epilepsy or seizure disorders, which are linked to cognitive decline and an increased risk of neurodegenerative diseases such as AD. Apart from that, gastrointestinal problems, anxiety, depression, and sleep disturbances are also frequent problems for those with autism. Chronic stress, inflammation, and metabolic dysregulation all of which are linked to the pathophysiology of AD may be exacerbated by these comorbidities. Additionally, social isolation and decreased cognitive stimulation might result from the communication and social interaction difficulties associated with ASD, which may hasten the advancement of dementia and cognitive decline in later years. Thus, recognizing and treating these comorbidities at an early age may be essential to reducing the likelihood that older autistic people will develop AD.[27,28]

Diagnostic Criteria for Alzheimer's Disease (AD)

Usually, a thorough evaluation is conducted to diagnose Alzheimer's disease, taking into account both clinical symptoms and, more and more, biomarkers. The generally used criteria are based on recommendations from organizations like the Alzheimer's Association and the National Institute on Aging (NIA-AA). The following are the main AD diagnostic criteria:

1. **Cognitive Impairment**: In one or more cognitive domains (memory, language, executive function, attention, perceptual-motor function, or social cognition), there is evidence of a cognitive decline from a prior level of performance.
2. **Interference with Daily Activities**: The person's cognitive impairments must make it difficult for them to carry out their regular daily activities or their job.
3. **Gradual Onset and Progressive Decline**: Over time, there should be a progressive decline in the cognitive deficiencies.
4. **Exclusion of Other Causes**: It is important to rule out other medical illnesses, psychological problems, and other neurodegenerative disorders as the main reasons of the cognitive abnormalities.
5. **Biomarkers (optional)**: In clinical practice, biomarkers, such as levels of tau and beta-amyloid proteins in cerebrospinal fluid or results from neuroimaging tests (MRI, PET scans), can help confirm the diagnosis but are not necessarily required.[29,30]

Diagnostic Criteria for Autism Spectrum Disorder (ASD)

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) contains the diagnostic criteria for ASD. A person must show confined, repetitive patterns of behavior, interests, or hobbies, as well as persistent deficiencies in social communication and social interaction across many situations, in order to be diagnosed with autism spectrum disorder (ASD). The following are the essential requirements:

1. **Persistent Deficits in Social Communication and Social Interaction**: Deficits in nonverbal communication behaviors employed in social interaction, social-emotional reciprocity, and building, sustaining, and comprehending relationships are all included in this.
2. **Restricted, Repetitive Patterns of Behavior, Interests, or Activities**: These include hyper- or hyporeactivity to sensory input, unusual interest in sensory aspects of the environment, and stereotyped

or repetitive motor movements, object use, or speech. They can also include an inflexible adherence to routines or an insistence on sameness.

3. **Symptoms Present Early in Development**: Early developmental stages must see the onset of symptoms, however they might not completely materialize until social needs surpass restricted abilities
4. **Clinically Significant Impairment**: The symptoms must result in a clinically noticeable impairment in crucial areas of current functioning, such as social or vocational.[31,32]

Challenges in Diagnosing AD in Autistic Patients

Identifying Alzheimer's disease in people with autism poses a number of particular difficulties, such as:

1. **Atypical Presentation**: People with autism may exhibit atypical symptoms of AD, which can make it challenging to distinguish between cognitive decline and current autism-related behavioral and cognitive patterns.
2. **Communication Difficulties**: Self-reporting of cognitive impairment may be hampered by poor verbal communication abilities or trouble conveying symptoms.
3. **Behavioral Overlap**: The presentation of overlapping behaviors, such as social disengagement or repetitive activities, between AD and autism can make it more difficult to interpret symptoms unique to AD.
4. **Age of Onset**: Many autistic people start their symptoms earlier in life, which could delay the identification of symptoms. The normal onset of AD is in later adulthood.
5. **Diagnostic Tools Adaptation**: To be used with autistic populations, standard cognitive exams and diagnostic instruments may require modification or extra validation.
6. **Caregiver Challenges**: When dealing with non-verbal or barely verbal autistic individuals, caregivers may find it difficult to identify and distinguish AD symptoms from the person's typical behaviors.

Current Treatments for Alzheimer's Disease (AD)

1. **Cholinesterase Inhibitors**: Medications such as galantamine, rivastigmine, and donepezil are frequently used to treat AD symptoms by boosting the brain's acetylcholine levels, which are low.
2. **NMDA Receptor Antagonist**: Memantine functions as an NMDA receptor antagonist to assist control brain glutamate activity, which is linked to memory and learning.
3. **Symptomatic Treatments**: Aggression, irritability, and sleep disruptions are examples of behavioral symptoms that can be controlled with medication.
4. **Non-Pharmacological Therapies**: These aim to preserve function and enhance quality of life. Examples of these include recollection therapy, reality orientation, and cognitive stimulation.
5. **Research into Disease-Modifying Therapies**: To possibly halt the progression of a disease, a number of experimental medications target tau protein tangles or beta-amyloid plaques.

Management Strategies for Autism Spectrum Disorder (ASD)

1. **Behavioral Therapies**: Applied Behavior Analysis (ABA) aims to improve social skills, communication, and adaptive living abilities by changing habits.
2. **Educational and Social Support**: Individuals with Autism Spectrum Disorder (ASD) benefit from regular routines, social skills training, and specialized education programs.
3. **Medications**: Certain symptoms, such irritability, aggression, anxiety, or hyperactivity, may be treated with certain drugs.
4. **Family Support and Counseling**: Giving families information and support enables them to comprehend and manage the difficulties brought on by ASD.
5. **Occupational Therapy and Sensory Integration**: Personalized therapy is used to address sensory sensitivity issues and enhance motor skills.

Integrated Therapeutic Approaches for Patients with Both AD and ASD

1. **Individualized Care Plans**: Creating customized treatment programs that take into account the needs unique to each individual with ASD, such as communication challenges and sensory sensitivity.
2. **Multi-Disciplinary Team Approach**: To coordinate care and address complicated requirements, experts from developmental pediatrics, neurology, psychiatry, and psychology are involved.
3. **Adapted Communication Strategies**: These involve using alternate communication techniques, simplified language, or visual aids to help patients understand and take part in therapeutic procedures.
4. **Caregiver Education and Support**: Giving caregivers guidance and assistance to control their conduct, keep an eye on medication compliance, and guarantee continuity of care.
5. **Environmental Modifications**: Establishing a sensory-friendly setting that reduces stress and fosters comfort for people with ASD and AD.[33,34,35]

FUTURE RESEARCH DIRECTIONS

In order to fill in knowledge gaps regarding diagnosis, treatment, and Alzheimer's disease (AD) and autism spectrum disorder (ASD), future research approaches may concentrate on a number of important areas:

1. **Epidemiological Studies**: Performing extensive epidemiological research to get further insight into the prevalence and incidence of AD in people with ASD, taking into account factors such as age of onset, course, and quality of life impact.

2. **Biomarker Development**: Finding and confirming biomarkers unique to autism in populations with autism, taking into account biochemical, genetic, and neuroimaging indicators that might be different from neurotypical AD..
3. **Diagnostic Tools**: Creating and approving diagnostic instruments specifically designed to identify AD in people with ASD at an early age, taking into consideration atypical symptoms and communication difficulties.
4. **Longitudinal Studies**: Conducting longitudinal studies to monitor behavioral and cognitive deterioration over time in people with ASD and AD, clarifying distinct patterns of progression and variables impacting the course of the disease.
5. **Treatment Trials**: Performing clinical trials to assess the safety and effectiveness of current AD medications (such as memantine and cholinesterase inhibitors) in individuals with autism, as well as investigating innovative therapies that target AD pathology unique to this population.
6. **Integrated Care Models**: This involves working with developmental pediatrics, neurology, psychiatry, and other specialties to design and test integrated care models that address the complex requirements of people with both ASD and AD.
7. **Quality of Life and Caregiver Burden**: Examining variables that impact the quality of life of people who have two diseases and assessing strategies to help caregivers successfully manage two conditions at once.
8. **Neurobiological Mechanisms**: Developing our understanding of the molecular, cellular, and genetic pathways involved in the onset and course of disease, as well as the neurobiological mechanisms underpinning the junction of AD and ASD.
9. **Educational and Supportive Interventions**: Creating and executing educational initiatives and supportive interventions that are adapted to the behavioral and cognitive characteristics of people with multiple disorders in order to foster self-sufficiency and overall wellbeing.
10. **Health Equity and Access**: Ensuring equitable care and support services for various populations with dual diagnoses of ASD and AD by addressing inequities in diagnosis, treatment results, and access to healthcare.

The scientific community can improve understanding, increase the precision of diagnoses, create focused treatments, and improve the quality of life for people who have both autism spectrum disorder and Alzheimer's disease by giving priority to these study areas.[36,37]

CONCLUSION

A crucial area of study in neurobiology is the intricate interactions between autism spectrum disorder (ASD) and Alzheimer's disease (AD). This review summarizes the state of current knowledge about the variables linked to the onset of Alzheimer's disease in people with autism, emphasizing a number of important discoveries and potential research directions. Initial research indicates that genetic susceptibility genes may have an impact on the onset and course of dementia in individuals with autism, indicating that genetic predispositions are important in both ASD and AD. Research has revealed shared genetic variations and pathways associated with neurodevelopmental problems and neurodegenerative diseases, highlighting the necessity for more genetic investigations to clarify particular mechanisms.

Second, an understanding of the increased risk of Alzheimer's in autistic individuals requires an understanding of neurobiological causes, such as changes in brain structure and function. Cognitive decline and early dementia onset in this population may be accelerated by structural variations in brain regions related to memory, cognition, and social processing. It will take further biomarker and neuroimaging research to fully understand these underlying mechanisms.

Furthermore, in autistic people, Alzheimer's risk may be modulated by the interaction of contextual factors, such as early life events, concomitant medical illnesses, and medication use, with genetic and neurobiological vulnerabilities. For the purpose of creating focused interventions and preventive measures, extensive longitudinal studies concentrating on these interactions are essential.

Crucially, providing care and therapeutic management for those with ASD and Alzheimer's disease simultaneously presents special difficulties. Optimizing the quality of life and functional results of these patients requires customized approaches that take into account their unique needs and skills.

In conclusion, there are still a great deal of unanswered questions despite tremendous advances in identifying the risk factors for the onset of Alzheimer's in autistic people. To further our understanding and treatment of Alzheimer's disease in the setting of autism spectrum disorder, future research endeavors should focus long-term studies, integrate a variety of genetic and neuroimaging techniques, and highlight personalized medicine approaches. By tackling these issues, we can open the door for more potent treatments and eventually enhance the situation for this susceptible group.

REFERENCES

1. Hickman RA, O'Shea SA, Mehler MF, Chung WK. Neurogenetic disorders across the lifespan: from aberrant development to degeneration. Nat Rev Neurol, Feb. 2022; 18(2): 117-124.
2. Maenner MJ, Shaw KA & Baio J. Prevalence of autism spectrum disorder among children aged 8 years – autism and developmental disabilities monitoring network, 11 sites, United States, 2016. *MMWR Surveill. Summ*, 2020; 69: 1–12.

3. DeTure, M.A., Dickson, D.W. The neuropathological diagnosis of Alzheimer's disease. *Mol Neurodegeneration*, 2019; 14: 32.
4. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, Dec. 8, 2020; 25(24): 5789.
5. Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Transl Pediatr, Feb. 2020; 9(1): S55-S65.
6. American Psychiatric Association. Diagnostic and statistcal manual of mental disorders. 4th ed. Washington: American Psychiatric Publishing, 1994.
7. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci, 2009; 11(2): 111-28.
8. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, Khaledi-Paveh B, Mohammadi M. The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis. Ital J Pediatr, Jul. 8, 2022; 48(1): 112.
9. Khan SA, Khan SA, Narendra AR, Mushtaq G, Zahran SA, Khan S, Kamal MA. Alzheimer's Disease and Autistic Spectrum Disorder: Is there any Association? CNS Neurol Disord Drug Targets, 2016; 15(4): 390-402.
10. Popa-Wagner A, Dumitrascu DI, Capitanescu B, Petcu EB, Surugiu R, Fang WH, Dumbrava DA. Dietary habits, lifestyle factors and neurodegenerative diseases. Neural Regen Res., Mar. 2020; 15(3): 394-400.
11. Yoon SH, Choi J, Lee WJ, Do JT. Genetic and Epigenetic Etiology Underlying Autism Spectrum Disorder. J Clin Med., Mar. 31, 2020; 9(4): 966.
12. Robert C, Pasquier L, Cohen D, Fradin M, Canitano R, Damaj L, Odent S, Tordjman S. Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy. Int J Mol Sci., Mar. 12, 2017; 18(3): 618.
13. Nadeem MS, Hosawi S, Alshehri S, Ghoneim MM, Imam SS, Murtaza BN, Kazmi I. Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer's Disease. Biomolecules, Nov. 4, 2021; 11(11): 1635.
14. Jiang CC, Lin LS, Long S, Ke XY, Fukunaga K, Lu YM, Han F. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. Signal Transduct Target Ther., Jul. 11, 2022; 7(1): 229.
15. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging, May-Jun, 2000; 21(3): 383-421.
16. Giri PM, Banerjee A, Ghosal A, Layek B. Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications. *International Journal of Molecular Sciences*, 2024; 25(7): 3995.
17. Robinson-Agramonte MLA, Noris García E, Fraga Guerra J, Vega Hurtado Y, Antonucci N, Semprún-Hernández N, Schultz S, Siniscalco D. Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It? Int J Mol Sci., Mar. 11, 2022; 23(6): 3033.
18. Erbescu A, Papuc SM, Budisteanu M, Arghir A, Neagu M. Re-emerging concepts of immune dysregulation in autism spectrum disorders. Front Psychiatry, Oct. 19, 2022; 13: 1006612.
19. Nabi SU, Rehman MU, Arafah A, Taifa S, Khan IS, Khan A, Rashid S, Jan F, Wani HA, Ahmad SF. Treatment of Autism Spectrum Disorders by Mitochondrial-targeted Drug: Future of Neurological Diseases Therapeutics. Curr Neuropharmacol, 2023; 21(5): 1042-1064.
20. Sultana MA, Hia RA, Akinsiku O, Hegde V. Peripheral Mitochondrial Dysfunction: A Potential Contributor to the Development of Metabolic Disorders and Alzheimer's Disease. *Biology*, 2023; 12(7): 1019.
21. Rhodus EK, Barber J, Abner EL, Bardach SH, Gibson A, Jicha GA. Comparison of behaviors characteristic of autism spectrum disorder behaviors and behavioral and psychiatric symptoms of dementia. Aging Ment Health, Mar. 2022; 26(3): 586-594.
22. Al-Mazidi SH. The Physiology of Cognition in Autism Spectrum Disorder: Current and Future Challenges. Cureus, Oct. 6. 2023; 15(10): e46581.
23. Lyall K, Schmidt RJ, Hertz-Picciotto I. Maternal lifestyle and environmental risk factors for autism spectrum disorders. Int J Epidemiol, Apr. 2014; 43(2): 443-64.
24. Davis R, Crompton CJ. What Do New Findings About Social Interaction in Autistic Adults Mean for Neurodevelopmental Research? Perspect Psychol Sci., May. 2021; 16(3): 649-653.
25. Burke SL, Cadet T, Alcide A, O'Driscoll J, Maramaldi P. Psychosocial risk factors and Alzheimer's disease: the associative effect of depression, sleep disturbance, and anxiety. Aging Ment Health, Dec. 2018; 22(12): 1577-1584.
26. Balasco L, Provenzano G, Bozzi Y. Sensory Abnormalities in Autism Spectrum Disorders: A Focus on the Tactile Domain, From Genetic Mouse Models to the Clinic. Front Psychiatry, Jan. 28, 2020; 10: 1016.
27. Vivanti G, Tao S, Lyall K, Robins DL, Shea LL. The prevalence and incidence of early-onset dementia among adults with autism spectrum

disorder. Autism Res., Oct. 2021; 14(10): 2189-2199.
28. Hsiao YH, Chang CH, Gean PW. Impact of social relationships on Alzheimer's memory impairment: mechanistic studies. J Biomed Sci., Jan. 11, 2018; 25(1): 3.
29. Schilling LP, Balthazar MLF, Radanovic M, Forlenza OV, Silagi ML, Smid J, Barbosa BJAP, Frota NAF, de Souza LC, Vale FAC, Caramelli P, Bertolucci PHF, Chaves MLF, Brucki SMD, Damasceno BP, Nitrini R. Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol, Nov. 28, 2022; 16(3,1): 25-39.
30. Okoye C, Obialo-Ibeawuchi CM, Obajeun OA, Sarwar S, Tawfik C, Waleed MS, Wasim AU, Mohamoud I, Afolayan AY, Mbaezue RN. Early Diagnosis of Autism Spectrum Disorder: A Review and Analysis of the Risks and Benefits. Cureus, Aug. 9, 2023; 15(8): e43226.
31. Global prevalence of autism: a systematic review update. Zeidan J, Fombonne E, Scorah J, et al. *Autism Res.*, 2022; 15: 778–790.
32. Park SH, Kwon KJ, Kim MY, Kim JH, Moon WJ, Ryu HJ, Jang JW, Moon Y; K-ARPI. Diagnostic Tools for Alzheimer's Disease: A Narrative Review Based on Our Own Research Experience. Dement Neurocogn Disord, Jan. 2023; 22(1): 16-27. doi: 10.12779/dnd.2023.22.1.16.
33. Rhodus EK, Barber J, Abner EL, Bardach SH, Gibson A, Jicha GA. Comparison of behaviors characteristic of autism spectrum disorder behaviors and behavioral and psychiatric symptoms of dementia. Aging Ment Health, Mar. 2022; 26(3): 586-594.
34. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord, Jan. 2013; 6(1): 19-33.
35. Chung KM, Chung E, Lee H. Behavioral Interventions for Autism Spectrum Disorder: A Brief Review and Guidelines With a Specific Focus on Applied Behavior Analysis. Soa Chongsonyon Chongsin Uihak, Jan. 1, 2024; 35(1): 29-38.
36. Damiano CR, Mazefsky CA, White SW, Dichter GS. Future directions for research in autism spectrum disorders. J Clin Child Adolesc Psychol, 2014; 43(5): 828-43.
37. Bishop-Fitzpatrick L, Kind AJH. A Scoping Review of Health Disparities in Autism Spectrum Disorder. J Autism Dev Disord, Nov. 2017; 47(11): 3380-3391.